Development of a Syngenic Murine B16 Cell Line-Derived Melanoma Susceptible to Destruction by Neuroattenuated HSV-1
Open Access
- 1 February 2001
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 3 (2) , 160-168
- https://doi.org/10.1006/mthe.2000.0240
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Combined Therapy with Chemotherapeutic Agents and Herpes Simplex Virus Type 1 ICP34.5 Mutant (HSV-1716) in Human Non-Small Cell Lung CancerHuman Gene Therapy, 1999
- Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccineGene Therapy, 1999
- Herpes Simplex Virus as an in Situ Cancer Vaccine for the Induction of Specific Anti-Tumor ImmunityHuman Gene Therapy, 1999
- Fotemustine and interferon à2b in metastatic malignant melanomaZeitschrift für Krebsforschung und Klinische Onkologie, 1998
- Herpesvirus Entry Mediator, a Member of the Tumor Necrosis Factor Receptor (TNFR) Family, Interacts with Members of the TNFR-associated Factor Family and Activates the Transcription Factors NF-κB and AP-1Journal of Biological Chemistry, 1997
- Long-Term Survival in a Rodent Model of Disseminated Brain Tumors by Combined Intrathecal Delivery of Herpes Vectors and Ganciclovir TreatmentHuman Gene Therapy, 1996
- Complementary DNA characterization and chromosomal localization of a human gene related to the poliovirus receptor-encoding geneGene, 1995
- Gene Transfer into Experimental Brain Tumors Mediated by Adenovirus, Herpes Simplex Virus, and Retrovirus VectorsHuman Gene Therapy, 1994
- Gene therapy of maliganant brain tumors: A rat glioma line bearing the herpes simplex virus type 1‐thymidine kinase gene and wild type retrovirus kills other tumor cellsJournal of Neuroscience Research, 1992
- Establishment of Four Functional, Clonal Strains of Animal Cells in CultureScience, 1966